Vensica is developing minimally invasive solutions in urology, using the unique properties of therapeutic ultrasound to deliver Botulinum Toxin A
Botulinum Toxin A is highly efficacious in several bladder indications, including Overactive Bladder, Neurogenic Bladder, and Painful Bladder Syndrome. However, the toxin is currently injected into the bladder wall in an invasive procedure that involves side effects, pain and anesthesia.
Bladder cancer: in addition to toxin delivery, Vensica is also working to improve bladder cancer treatment with its proprietary platform.
Vensica developed a proprietary minimally invasive, needle-free device to deliver botulinum toxin A to the bladder. Vensica’s procedure is very simple and quick both for the urologist and the patient.
No needles, no anesthesia, and no cystoscopy required.
Overactive Bladder: Over 4 million patients fail oral medication treatment and seek a non-invasive solution to their illness.
Neurogenic Bladder: Over 1.5 million patients do not respond positively to oral medication treatment and seek a non-invasive solution to their illness.
Painful Bladder Syndrome: No effective treatment available for the 2 million patients in the USA.
Vensica is a clinical stage biopharmaceutical company, founded in 2014 by Avner Geva to improve incontinence and bladder cancer treatments.
Since then the company has expanded with the recruitment of a team of world-leading urology experts, the signing of agreements with global companies, and the completion of a very successful clinical pilot trial.
10 years of experience in the life sciences industry. Yale Bsc (Biology), Technion MSc (Biomedical Engineering).
Senior manager, Oribmed Israel. Led number of companies to successful exits.
Extensive experience in leading start ups from inception to go-to-market. Technion MSc, System Engineering.
Sign up to hear from us